Financial Performance - The company's operating revenue for the first half of 2023 was CNY 40.156 billion, representing a 4.69% increase compared to CNY 38.356 billion in the same period last year[22]. - The net profit attributable to shareholders of the listed company was CNY 745,131.66, a significant decrease of 98.81% from CNY 62.860 million in the previous year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY -196.052 million, a decline of 324.85% compared to CNY -46.146 million in the same period last year[22]. - The net cash flow from operating activities was CNY 53.720 million, a turnaround from a negative cash flow of CNY -1.616 billion in the previous year, marking a 103.32% improvement[22]. - Total assets at the end of the reporting period reached CNY 9.329 billion, an increase of 19.71% from CNY 7.793 billion at the end of the previous year[22]. - The net assets attributable to shareholders of the listed company were CNY 3.037 billion, showing a slight increase of 0.66% from CNY 3.017 billion at the end of the previous year[22]. - The basic earnings per share decreased to CNY 0.0015, down 98.79% from CNY 0.1235 in the same period last year[22]. - The diluted earnings per share also fell to CNY 0.0015, reflecting the same percentage decrease of 98.79% compared to the previous year[22]. - The weighted average return on net assets was 0.02%, a decrease of 2.13% from 2.15% in the previous year[22]. - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[5]. Business Strategy and Operations - The company is transitioning from a trading firm to an integrated high-tech enterprise, focusing on commodity trading, oil, and bio-agriculture[31]. - The oil and fat sector includes a comprehensive supply chain from production to consumer, with major products like palm oil and specialty oils[33]. - The company operates over 400 upstream and downstream clients, including well-known enterprises like COFCO and Yihai Kerry[33]. - The acquisition of a palm oil refinery in Malaysia enhances the company's control over processing resources in the palm oil value chain[35]. - The company has established over 30 subsidiaries and has a strategic presence in multiple countries[30]. - The company emphasizes R&D, holding over 40 invention patents and participating in the formulation of 7 industry or national standards[30]. - The company has strengthened its R&D and channel expansion for specialty oils, introducing high-end products like Irish natural fermented butter with high fat content and rich flavor[37]. - The company launched customized high-end edible oil products for industrial clients, including sheet-style and flavored cream products, enhancing collaboration with major clients[37]. - The company participated in major baking exhibitions, showcasing innovative products and solutions to meet diverse customer needs in the baking industry[37]. Research and Development - The company has established a professional R&D team in the bio-agriculture sector, focusing on microbial and crop biotechnology, with over 40 patents related to bio-agriculture[39]. - The acquisition of Maike Biological in January 2023 is a strategic move to enhance the company's product portfolio in bio-agriculture, with over 50 products exported to more than 30 countries[41]. - Maike Biological has advanced production lines and has been recognized as a "green factory" and "green product" by various authorities, holding 25 invention patents[41]. - The company has conducted over 400 promotional events nationwide, achieving over 100,000 views for online observation meetings, enhancing its bio-agriculture service capabilities[42]. - The sales proportion of formulation products has rapidly increased, with successful field promotions of the Junmao® product line for major crops[42]. - The company is focused on improving production processes and expanding its product line in bio-agriculture, aiming to establish a mature industrial system by 2025[41]. - The company has received multiple provincial awards for its innovative capabilities and is committed to enhancing its profitability and sustainable development in the bio-agriculture sector[42]. Risk Management - The company has developed a comprehensive risk management system, optimizing its risk control measures based on total asset management, ensuring effective execution[44]. - The company has implemented measures to monitor and manage financial and operational risks in subsidiaries[60]. - The company has established a risk management framework to address potential risks from futures and derivatives investments, including liquidity and credit risks[81]. - The company has implemented strategies to mitigate foreign exchange risks that could impact import costs and export revenues[82]. - The company aims to integrate high-tech assets through acquisitions while managing goodwill and integration risks[83]. Environmental and Social Responsibility - Kairui Bio and Maikelu Bio are classified as key pollutant discharge units by environmental protection authorities[92]. - Kairui Bio's wastewater treatment plant has a designed capacity of 200 m³/d, utilizing a multi-step treatment process[96]. - Kairui Bio's total wastewater discharge includes 0.2454 tons of COD and 0.004436 tons of ammonia nitrogen per year, both within regulatory limits[94]. - Kairui Bio has implemented comprehensive wastewater and air pollution control measures, including recycling and treatment systems[96]. - The company has established a 260 m³ emergency pool for environmental risk prevention[97]. - The company actively engages in social responsibility initiatives, such as the "Yuan Da An Xin Village" project, to support local communities[107]. Shareholder and Corporate Governance - The company reported a total of 34.80 million yuan involved in minor litigation cases, with no significant impact on the company[117]. - The company and its controlling shareholders had no integrity issues during the reporting period[118]. - The company reported a total owner's equity of 4,760 million yuan for the first half of 2023, up from 4,517 million yuan in the previous period, marking a growth of 5.36%[190]. - The financial report was approved by the board of directors on August 24, 2023[195]. - The company has not engaged in any significant equity investments during the reporting period[65]. Future Outlook - The company has provided a future outlook projecting a revenue growth of approximately 20% for the next fiscal year, driven by new product launches and market expansion strategies[131]. - Future guidance indicates an expected revenue growth of 10% for the second half of 2023, driven by new product launches and market expansion strategies[182]. - The company plans to continue expanding its market presence and invest in new product development in the upcoming quarters[189].

远大产业控股股份有限公司 独立董事专项说明和独立意见 作为公司独立董事，本着认真负责的态度，基于独立、客观判断立场，根据 中国证监会"证监发(2003)56号"文《关于规范上市公司与关联方资金往来及上 市公司对外担保若干问题的通知》和江苏证监局"苏证监公司字（2008）325号" 文《关于进一步规范上市公司与大股东及其他关联方资金往来的通知》的要求， 认真核查了公司与控股股东及其他关联方资金往来、资金占用的情况，对2023 年半年度控股股东及其他关联方占用公司资金、公司对外担保情况发表专项说明 和独立意见如下： 一、2023年半年度，公司不存在控股股东及其它关联方非经营性占用公司资 金等情况。 3 | 宁波远大国际贸易有限公司 2022 年 12 月 26 日 | | 7,143 | 2022 年 12 月 26 日 | 4,999.40 | 连带责 | 1 年 | 否 | 否 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 任担保 | | | | | 宁波远大国际贸易有限公司 | 2023 年 5 月 9 日 | 7 ...

远大产业控股股份有限公司 远大产业控股股份有限公司 控股股东及其他关联方非经营性资金占用及清偿情况表 控股股东或其 他关联方名称 占用 时间 发生 原因 期初余额（2023 年 1 月 1 日） 报告期新增占用金额 （2023 年 1-6 月） 报告期偿还总金额 （2023 年 1-6 月） 期末余额（2023 年 6 月 30 日） 截至半年报 披露日余额 预计偿 还方式 预计偿 还金额 预计偿还时 间（月份） 当年新增非经营性资金占用情况的原因、责任人追究及董事会拟定采取措 施的情况说明 未能按计划清偿非经营性资金占用的原因、责任追究情况及董事会拟定采 取的措施说明 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 公司负责人：史迎春 主管会计工作的负责人：苏原 会计机构负责人：苏原 单位：人民币万元 非经营性资金占用 资金占用方名称 占用方与上市 公司的关联关 系 上市公司核算 的会计科目 2023 年期初占 用资金余额 2023 年半年度占 用累计发生金额 （不含利息） 2023 年半 年度占用资 金的利息 2023 年半年 度偿还累计 发生金额 2023 年半年 度期末占用 资金余额 ...

证券代码：000626 证券简称：远大控股 公告编号：2023-048 远大产业控股股份有限公司 为更加真实、准确地反映远大产业控股股份有限公司（以下简称：公司）2023 年 6 月 30 日的财务状况以及 2023 年上半年度经营成果，根据《企业会计准则》 及公司会计政策等相关规定，公司及下属子公司基于谨慎性原则，对各类资产进 行了清查、分析和评估，对部分可能发生信用及资产减值的资产计提了减值准备。 公司 2023 年上半年度（以下简称：本期）计提各项信用及资产减值准备具 体情况见下表： 单位：万元 | 项目 | 期初余额 | | 本期变动金额 | | | 期末余额 | | --- | --- | --- | --- | --- | --- | --- | | | | 计提 | 转回 | 转销/核销 | 其他 | | | 一、坏账准备 | 45,928.91 | 2,692.71 | 4,600.91 | 38,888.33 | -388.42 | 5,520.80 | | 其中：应收账款 | 22,384.00 | 989.86 | 3,429.14 | 15,085.31 | -78.81 | 4,93 ...

证券代码：000626 证券简称：远大控股 公告编号：2023-046 2、审议通过了《关于全资子公司核销坏账的议案》。 公司全资子公司远大物产集团有限公司、宁波远大国际贸易有限公司对已全 额计提坏账准备的 423,297,714.55 元坏账进行核销，本次坏账核销不影响公司 本年利润，不涉及公司关联方，不存在损害公司和股东利益的情形。 本议案获得的同意票数为 13 票、获得的反对票数为 0 票、获得的弃权票数 为 0 票，议案获得通过。 远大产业控股股份有限公司董事会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、会议召开情况 远大产业控股股份有限公司(以下简称：公司)第十届董事会 2023 年度第七 次会议通知于 2023 年 8 月 22 日以电子邮件方式发出，会议于 2023 年 8 月 24 日 以通讯方式召开。本次会议应出席的董事人数为 13 名，实际出席的董事人数为 13 名，公司监事列席了本次会议。本次会议由董事长史迎春先生主持，会议的召 开符合有关法律、行政法规、部门规章、规范性文件和公司章程的规定。 二、会议审议情况 1、审议 ...

证券代码：000626 证券简称：远大控股 远大产业控股股份有限公司投资者关系活动记录表 编号：2023-001 | 投资者关系活动类别 | □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 □其他（请文字说明其他活动内容） | | 活动参与人员 | 通过同花顺路演平台参与 2022 年度网上业绩说明会的投资者 | | 时间 | 2023 年 5 月 18 日 15:00-16:00 | | 地点 | 同花顺路演平台（https://board.10jqka.com.cn/ir）。 | | 形式 | 线上文字直播 | | | 公司于 2023 年 5 月 18 日下午 15:00-16: 00 以网络文字互动的 | | | 方式召开了 2022 年度网上业绩说明会。公司董事长兼总裁史迎春先 | | | 生、独立董事吴价宝先生、副董事长兼副总裁许强先生、副总裁姜勇 | | | 先生、董事会秘书代财务总监朱丰超先生参加了本次说明会，在信息 | | | 披露允许的范围内就投资者关注的事项与投资者进行了沟通与交 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 远大产业控股股份有限公司(以下简称：公司) 2022 年度报告已于 2023 年 4 月 25 日发布。为便于广大投资者进一步了解公司情况，加强投资者关系管理， 增进公司与广大投资者的沟通与交流，公司定于 2023 年 5 月 18 日（星期四）在 同花顺路演平台举办 2022 年度业绩说明会，具体安排如下： 证券代码：000626 证券简称：远大控股 公告编号：2023-030 远大产业控股股份有限公司 关于举行网上业绩说明会的公告 一、说明会召开时间、地点及方式 1、时间 2023 年 5 月 18 日（星期四）下午 15:00-16:00。 2、会议召开地点: 同花顺路演平台 （https://board.10jqka.com.cn/rs/pc/detail?roadshowId=1005685）。 3、会议召开方式 网络形式。 二、公司参会人员 公司出席本次业绩说明会的人员有：董事长兼总裁史迎春先生、独立董事吴 价宝先生、副董事长兼副总裁许强先生、副总裁姜勇先生、董事会秘书代财务总 监朱丰超先生。（如有特 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥17,517,695,932.01, representing a 2.58% increase compared to ¥17,076,716,532.60 in the same period last year[6] - Net profit attributable to shareholders was ¥15,654,959.42, a significant increase of 40.41% from ¥11,149,720.14 in the previous year[6] - The company's basic earnings per share increased by 50.00% to ¥0.03, up from ¥0.02 in the same period last year[6] - In Q1 2023, the company achieved a revenue of 17.518 billion RMB, representing a year-on-year growth of 2.58%[17] - The net profit attributable to shareholders in Q1 2023 was 15.6549 million RMB, an increase of 40.41% compared to the same period last year[17] - Total operating costs for Q1 2023 were CNY 17,576,500,426.99, an increase from CNY 17,044,678,320.17 in Q1 2022, representing a growth of approximately 3.12%[35] - The company reported a total comprehensive income of CNY 13,947,843.42 for Q1 2023, compared to CNY 12,830,192.60 in Q1 2022, marking an increase of about 8.7%[36] Cash Flow and Financial Position - The net cash flow from operating activities improved to -¥801,245,598.78, a 32.75% reduction in losses compared to -¥1,191,402,355.34 in the same period last year[6] - The net cash flow from operating activities for Q1 2023 was -801,245,598.78, an improvement from -1,191,402,355.34 in Q1 2022, indicating a reduction in cash outflow[38] - The total cash inflow from operating activities was 21,381,354,028.73, compared to 18,606,675,308.77 in Q1 2022, showing growth in operational cash generation[38] - The total cash outflow from operating activities was 22,182,599,627.51, an increase from 19,798,077,664.11 in the previous year, indicating higher operational costs[38] - The cash and cash equivalents decreased to CNY 2,533,762,346.11 from CNY 2,753,973,619.75, a decline of about 7.98%[31] - The ending balance of cash and cash equivalents was 1,589,764,281.58, down from 2,249,131,730.86 in the previous year[39] Assets and Liabilities - Total assets at the end of Q1 2023 reached ¥9,689,589,496.22, marking a 24.34% increase from ¥7,792,783,558.14 at the end of the previous year[6] - The total current assets at the end of Q1 2023 amounted to CNY 7,500,128,242.38, up from CNY 6,129,987,554.72 at the beginning of the year, indicating a growth of about 22.34%[31] - The total liabilities as of March 31, 2023, were CNY 6,469,900,893.18, compared to CNY 4,515,488,519.32 at the start of the year, reflecting an increase of approximately 43.25%[32] - The company's total equity decreased slightly to CNY 3,219,688,603.04 from CNY 3,277,295,038.82, a decline of approximately 1.75%[32] Investments and Acquisitions - The company reported a significant increase in goodwill by 137.27% to ¥1,005,961,696.84 following the acquisition of Maikeluoluo Biotechnology[10] - The company has successfully completed the acquisition of Microlife Biotech, which specializes in over 50 types of biopesticides, expanding its product offerings in the agricultural sector[25] - The company’s investment income surged by 2634.94% to ¥74,773,994.00, driven by higher profits from derivative trading[10] Inventory and Borrowings - The company’s inventory increased by 124.04% to ¥2,222,055,904.07, attributed to increased stockpiling in response to commodity trading conditions[10] - The company’s short-term borrowings rose by 148.09% to ¥1,018,189,057.37, reflecting an increase in financing needs[10] Research and Development - Research and development expenses increased significantly to CNY 2,663,221.42 in Q1 2023 from CNY 210,789.67 in Q1 2022, indicating a rise of approximately 1165.4%[35] - The company has a strong focus on R&D, with over 40 patents related to biopesticides and has received multiple provincial and national awards for its innovations[23][24] Market and Customer Base - The company has established a strong customer base with over 400 upstream and downstream clients, including well-known enterprises like COFCO and Yihai Kerry[20] - The company has enhanced its agricultural promotion services, conducting over 200 promotional events nationwide, reaching over 100,000 views online[27] - The company has seen a rapid increase in the sales proportion of its formulation products, indicating a successful marketing strategy[27] Product Development - The company has introduced high-end products using Irish natural fermented cream and high-end tart crust oil, targeting the baking market[22] - The company aims to establish a mature biopesticide industrial system by 2025, focusing on R&D, production, and market promotion[26]

Financial Performance - The company's operating revenue for 2022 was ¥82,007,904,175.91, representing a 0.55% increase from ¥81,561,908,376.25 in 2021[20] - The net profit attributable to shareholders decreased by 48.41% to ¥114,594,011.79 from ¥222,141,582.30 in the previous year[20] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥174,665,916.48, a decline of 264.62% compared to ¥106,101,976.91 in 2021[20] - The net cash flow from operating activities was -¥841,937,116.50, a decrease of 209.69% from ¥767,587,134.79 in 2021[20] - Basic earnings per share fell by 46.51% to ¥0.23 from ¥0.43 in the previous year[20] - Total assets at the end of 2022 were ¥7,792,783,558.14, an increase of 2.15% from ¥7,628,880,311.03 at the end of 2021[20] - The net assets attributable to shareholders increased by 4.72% to ¥3,016,755,419.93 from ¥2,880,831,939.26 in 2021[20] - The company reported a significant uncertainty regarding its ability to continue as a going concern[20] Revenue Breakdown - The company’s revenue after deducting certain amounts was ¥82,002,871,540.99, slightly higher than ¥81,558,019,152.38 in 2021[20] - The company's total revenue for Q1 was approximately ¥17.08 billion, Q2 was ¥21.28 billion, Q3 was ¥23.31 billion, and Q4 was ¥20.35 billion, showing a significant increase in Q3 compared to Q1[24] - The net profit attributable to shareholders for Q1 was approximately ¥11.15 million, Q2 was ¥51.71 million, Q3 was ¥58.23 million, while Q4 recorded a loss of approximately ¥6.50 million[24] - The net profit attributable to shareholders after deducting non-recurring gains and losses was negative in Q2, Q3, and Q4, with figures of approximately -¥51.53 million, -¥32.82 million, and -¥95.70 million respectively[24] - Cash flow from operating activities was negative in Q1 at approximately -¥1.19 billion, improved to -¥424.60 million in Q2, positive at ¥1.67 billion in Q3, and again negative at -¥899.85 million in Q4[24] Government Support and Industry Trends - The company reported a government subsidy of approximately ¥72.55 million in 2022, an increase from ¥61.75 million in 2021 and ¥50.67 million in 2020[26] - The trading industry is transitioning from high-speed growth to high-quality development, requiring enhanced price management and resource integration capabilities[32] - The oil and fat industry is expected to grow, driven by increasing consumer demand for healthy and safe food products, with a focus on high-end edible oils[34] - The special oil industry is projected to grow significantly, with the baking food market expected to exceed ¥300 billion in 2023, indicating strong potential for growth[36] Business Operations and Strategy - The company has established a full industry chain operating model in the oil sector, focusing on palm oil and other edible oils, leveraging years of industry experience[35] - The bio-agriculture sector emphasizes high-tech and efficient agricultural production methods, aiming to improve production efficiency and achieve ecological balance[38] - The company focuses on the biological agriculture sector, with a core development direction centered on biopesticides and plant nutrition[40] - The company has established over 30 wholly-owned and holding subsidiaries, ranking 164th on the 2022 Fortune China 500 list[41] - The company holds over 40 invention patents and has participated in the formulation of 7 industry or national standards[41] - The company’s oil and fat business includes a total storage capacity of 177,000 cubic meters, making it one of the largest edible oil storage enterprises in South China[45] - The company’s subsidiary, Hongxin Foods, specializes in producing edible specialty oils and has received multiple quality management certifications[46] - The company is committed to sustainable development and has aligned its strategies with national policies on food security and environmental protection[40] Acquisitions and Investments - The company acquired 100% equity of the palm oil refining plant in Johor, Malaysia, enhancing its palm oil refining, fractionation, packaging, and sales capabilities[57] - The acquisition of the Johor facility is part of the company's strategy to strengthen its position in the palm oil industry chain and improve collaboration with upstream and downstream partners[48] - The company has implemented several acquisitions, including Hongxin Food and a palm oil refining plant in Malaysia, to strengthen its industrial foundation[64] - The company acquired 80% of Hongxin Food in April 2022, entering the specialty oils sector, which has significant growth potential and high synergy with existing palm oil and soybean oil products[67] - In October 2022, the company acquired a palm oil refining plant in Malaysia, enhancing its position in the palm oil value chain and improving its credibility and confidence in expanding downstream operations[68] Research and Development - The company has a strong research capability, utilizing accumulated data to study industry cycles and provide value-added services to clients[54] - The company has received multiple provincial and national technology awards, highlighting its commitment to innovation and quality in its products[51] - The company has launched 14 new products and optimized 63 formulas in the specialty oils business, enhancing customer engagement and market competitiveness[69] - The company has focused on risk management and optimized its organizational structure to improve operational efficiency and market competitiveness[66] - Research and development expenses surged by 323.52% to 8,254,757.68 CNY in 2022, up from 1,949,105.47 CNY in 2021, primarily due to increased investments in the bio-agriculture and oil sectors[87] Risk Management - The company has established a comprehensive risk management system based on total assets, optimizing and upgrading it to ensure effective risk control during profit generation[55] - The company has implemented a risk management system for futures and derivatives trading, focusing on compliance and risk control, with dedicated risk control teams for both spot and futures markets[128] - The company has established strategies to mitigate foreign exchange risks, utilizing appropriate hedging tools to minimize the impact of currency fluctuations on its operating performance[129] Corporate Governance - The company has maintained compliance with corporate governance regulations, ensuring that its governance structure aligns with the requirements set by regulatory authorities[134] - The company has ensured the independence of its assets, personnel, finances, institutions, and business from its controlling shareholders, maintaining operational autonomy[135] - The company has not engaged in any activities that would compromise its independence, such as sharing resources or financial accounts with its controlling shareholders[136] - The company held a total of seven temporary shareholder meetings in 2022, with investor participation rates ranging from 57.36% to 58.86%[139] - The company’s governance structure is being reviewed to ensure compliance and effectiveness following recent personnel changes[144] Employee Management - The total number of employees at the end of the reporting period is 1,039, including 50 at the parent company and 989 at major subsidiaries[164] - The employee composition includes 273 production personnel, 269 sales personnel, 44 technical personnel, 93 financial personnel, 160 administrative personnel, 45 R&D personnel, and 155 other business assistants[165] - The company emphasizes a performance and value-oriented salary policy, considering job value, performance contribution, and individual capability[166] - The employee training program includes new employee training, probation guidance, professional skills training, and management training[167] Environmental Responsibility - The company has reported no exceedances of pollutant discharge limits during the reporting period[185] - The company has committed to providing equal employment opportunities and maintaining employee rights in accordance with national labor laws[192] - The company has initiated the "Yuan Da Anxin Village" social welfare project, promoting community engagement through various activities[193] - The company has implemented clean production technologies to reduce carbon emissions and wastewater discharge during the production process[191]

[Report Statement and Important Notice](index=1&type=section&id=%E6%8A%A5%E5%91%8A%E5%A3%B0%E6%98%8E%E4%B8%8E%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA) This section contains the company's declaration regarding the report's accuracy and highlights that the report is unaudited [Statement](index=1&type=section&id=%E5%A3%B0%E6%98%8E) The board, supervisory board, and senior management affirm the quarterly report's truthfulness, accuracy, and completeness - Board, supervisory board, and senior management guarantee the **truthfulness, accuracy, and completeness** of the quarterly report[2](index=2&type=chunk)[3](index=3&type=chunk) - Company head, chief accountant, and accounting department head declare financial information is **true, accurate, and complete**[3](index=3&type=chunk) [Important Notice](index=1&type=section&id=%E9%87%8D%E8%A6%81%E5%86%85%E5%AE%B9%E6%8F%90%E7%A4%BA) This quarterly report has not been audited - The third-quarter report is **unaudited**[4](index=4&type=chunk) [Key Financial Data](index=2&type=section&id=%E4%B8%80%E3%80%81%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%95%B0%E6%8D%AE) This section presents the company's main accounting data and financial indicators, including revenue, net profit, and cash flow [Key Accounting Data and Financial Indicators](index=2&type=section&id=%EF%BC%88%E4%B8%80%EF%BC%89%20%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) Q3 revenue increased by **15.58%** year-on-year, but net profit attributable to shareholders decreased by **28.48%** | 指标 | 本报告期 (CNY) | 本报告期比上年同期增减 | 年初至报告期末 (CNY) | 年初至报告期末比上年同期增减 | | :--- | :--- | :--- | :--- | :--- | | 营业收入 | 23,305,561,070.12 | 15.58% | 61,661,629,248.21 | 2.63% | | 归属于上市公司股东的净利润 | 58,233,897.02 | -28.48% | 121,093,980.48 | -43.28% | | 归属于上市公司股东的扣除非经常性损益的净利润 | -32,818,412.34 | 12.31% | -78,964,905.30 | -177.44% | | 经营活动产生的现金流量净额 | — | — | 57,908,724.46 | -81.20% | | 基本每股收益（CNY/Share） | 0.12 | -25.00% | 0.24 | -41.46% | | 稀释每股收益（CNY/Share） | 0.12 | -25.00% | 0.24 | -41.46% | | 加权平均净资产收益率 | 1.96% | -0.93% | 4.11% | -3.67% | | **本报告期末** | **上年度末** | **本报告期末比上年度末增减** | | | | 总资产 | 8,986,884,260.53 | 7,628,880,311.03 | 17.80% | | | 归属于上市公司股东的所有者权益 | 3,024,294,598.51 | 2,880,831,939.26 | 4.98% | | - Net profit decline is mainly due to macro factors like the Russia-Ukraine war, global pandemic, commodity price fluctuations, logistics disruptions, and Fed interest rate hikes[5](index=5&type=chunk) - Net profit after non-recurring items is negative, primarily because futures derivative gains and fair value changes are classified as non-recurring, not affecting actual operating capability[6](index=6&type=chunk) [Non-Recurring Gains and Losses Items and Amounts](index=2&type=section&id=%EF%BC%88%E4%BA%8C%EF%BC%89%20%E9%9D%9E%E7%BB%8F%E5%B8%B8%E6%80%A7%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%92%8C%E9%87%91%E9%A2%9D) Non-recurring gains and losses mainly comprise asset disposal losses, government subsidies, and financial asset fair value changes | 项目 | 本报告期金额 (CNY) | 年初至报告期期末金额 (CNY) | 说明 | | :--- | :--- | :--- | :--- | | 非流动资产处置损益 | -4,976,986.98 | -4,548,485.45 | 处置全资子公司BRILLIANCE RESOURCES (USA) Inc 100%股权确认的亏损额 | | 计入当期损益的政府补助 | 314,459.56 | 60,936,224.92 | 主要是全资子公司远大物产集团有限公司及其子公司收到的产业转型升级及企业扶持专项补助资金 | | 除同公司正常经营业务相关的有效套期保值业务外，持有交易性金融资产、交易性金融负债产生的公允价值变动损益，以及处置交易性金融资产、交易性金融负债和可供出售金融资产取得的投资收益 | 104,687,073.25 | 228,885,481.60 | 主要为公司为配套主营业务现货经营，合理运用期货工具和外汇合约对冲大宗商品价格及汇率波动风险，相应产生的公允价值变动损益及处置损益，该损益与主营业务经营损益密切相关 | | 除上述各项之外的其他营业外收入和支出 | 6,373,840.16 | 11,920,224.12 | | | 减：所得税影响额 | 15,062,366.40 | 67,645,203.22 | | | 少数股东权益影响额（税后） | 283,710.24 | 29,489,356.19 | | | 合计 | 91,052,309.35 | 200,058,885.78 | -- | - The company does not classify non-recurring items as recurring[10](index=10&type=chunk) [Changes and Reasons for Key Accounting Data and Financial Indicators](index=3&type=section&id=%EF%BC%88%E4%B8%89%EF%BC%89%20%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87%E5%8F%91%E7%94%9F%E5%8F%98%E5%8A%A8%E7%9A%84%E6%83%85%E5%86%B5%E5%8F%8A%E5%8E%9F%E5%9B%A0) Company's financial statements show significant changes influenced by futures, M&A, R&D, exchange rates, and business strategy adjustments [Changes in Consolidated Balance Sheet Items](index=3&type=section&id=1%E3%80%81%E5%90%88%E5%B9%B6%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8%E9%A1%B9%E7%9B%AE) Balance sheet changes reflect increases in derivative financial assets, fixed assets, and contract liabilities, alongside decreases in equity investments | 报表项目 | 期末余额 (CNY) | 期初余额 (CNY) | 变动比例 (%) | 变动原因 | | :--- | :--- | :--- | :--- | | 衍生金融资产 | 70,915,250.66 | 34,309,964.51 | 106.69% | 期货合约浮动盈利增加 | | 其他权益工具投资 | - | 24,185,079.72 | -100.00% | 处置宁波远大实业投资有限公司股权 | | 固定资产 | 352,232,753.60 | 258,090,411.88 | 36.48% | 收购广东鸿信食品有限公司后固定资产价值增加 | | 在建工程 | 11,887,733.87 | 29,082,884.47 | -59.12% | 远大中心装修项目转入固定资产 | | 使用权资产 | 105,805,208.31 | 66,262,628.29 | 59.68% | 签订公司分部长期租赁合同 | | 无形资产 | 149,623,773.54 | 90,881,489.92 | 64.64% | 收购鸿信食品后无形资产价值增加 | | 开发支出 | 11,758,484.61 | 7,649,508.83 | 53.72% | 生态农业领域持续研发投入 | | 交易性金融负债 | 89,407,022.96 | 27,471,935.72 | 225.45% | 现货合约浮动亏损增加 | | 应付票据 | 1,599,220,680.00 | 865,418,000.00 | 84.79% | 采购环节扩大了票据模式的结算 | | 合同负债 | 1,060,880,076.16 | 713,922,003.87 | 48.60% | 期末签订的销售合约大于期初，预收款项增加 | | 其他应付款 | 111,245,940.33 | 73,713,132.17 | 50.92% | 鸿信食品账面应分配原股东股利 | | 长期借款 | 307,437,700.00 | 225,921,600.00 | 36.08% | 新增并购贷款 | | 租赁负债 | 92,273,213.51 | 43,627,913.75 | 111.50% | 签订公司分部长期租赁合同 | | 长期应付职工薪酬 | 85,585,964.24 | 154,295,808.33 | -44.53% | 经营业绩变化导致计提业绩奖励等减少 | | 递延所得税负债 | 17,342,915.21 | 9,996,017.79 | 73.50% | 鸿信食品账面金额合并增加 | | 其他综合收益 | -31,472,169.73 | -79,040,625.02 | 60.18% | 外币报表折算差异 | [Changes in Consolidated Income Statement Items](index=4&type=section&id=2%E3%80%81%E5%90%88%E5%B9%B6%E5%88%A9%E6%B6%A6%E8%A1%A8%E9%A1%B9%E7%9B%AE) Income statement changes show a significant increase in R&D expenses and financial expenses, while sales expenses and credit impairment losses decreased | 报表项目 | 本期发生额 (CNY) | 上期发生额 (CNY) | 变动比例 (%) | 变动原因 | | :--- | :--- | :--- | :--- | | 税金及附加 | 24,760,451.06 | 18,951,924.10 | 30.65% | 印花税较上年有所增加 | | 销售费用 | 238,773,317.29 | 357,003,835.16 | -33.12% | 经营业绩变化导致计提业绩奖励等减少 | | 研发费用 | 4,010,517.36 | 289,345.55 | 1286.06% | 生态农业领域持续研发投入 | | 财务费用 | 58,882,283.13 | 34,226,292.90 | 72.04% | 汇率波动导致汇兑损失增加 | | 公允价值变动收益 | -60,907,136.44 | -210,179,232.34 | 71.02% | 本年交易性金融资产和衍生品浮动亏损净额小于上年同期 | | 信用减值损失 | -3,529,698.27 | -12,246,416.51 | 71.18% | 坏账损失较上年同期减少 | | 营业外收入 | 12,812,552.75 | 9,230,223.08 | 38.81% | 违约金赔偿金收入较上年同期增加 | [Changes in Consolidated Cash Flow Statement Items](index=4&type=section&id=3%E3%80%81%E5%90%88%E5%B9%B6%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8%E9%A1%B9%E7%9B%AE) Operating, investing, and financing cash flows all significantly decreased year-on-year due to increased purchases and reduced financing | 报表项目 | 本期发生额 (CNY) | 上期发生额 (CNY) | 变动比例 (%) | 变动原因 | | :--- | :--- | :--- | :--- | | 经营活动产生的现金流量净额 | 57,908,724.46 | 307,949,261.94 | -81.20% | 商品采购支付的现金同比增加 | | 投资活动产生的现金流量净额 | 70,131,150.06 | 638,327,406.91 | -89.01% | 理财赎回收到的现金同比减少 | | 筹资活动产生的现金流量净额 | 153,649,007.26 | 360,188,841.29 | -57.34% | 融资规模同比减少 | [Shareholder Information](index=4&type=section&id=%E4%BA%8C%E3%80%81%E8%82%A1%E4%B8%9C%E4%BF%A1%E6%81%AF) This section details the total number of common shareholders and the top ten shareholders' holdings [Total Number of Common Shareholders and Top Ten Shareholders' Holdings](index=4&type=section&id=%EF%BC%88%E4%B8%80%EF%BC%89%20%E6%99%AE%E9%80%9A%E8%82%A1%E8%82%A1%E4%B8%9C%E6%80%BB%E6%95%B0%E5%92%8C%E8%A1%A8%E5%86%B3%E6%9D%83%E6%81%A2%E5%A4%8D%E7%9A%84%E4%BC%98%E5%85%88%E8%82%A1%E8%82%A1%E4%B8%9C%E6%95%B0%E9%87%8F%E5%8F%8A%E5%89%8D%E5%8D%81%E5%90%8D%E8%82%A1%E4%B8%9C%E6%8C%81%E8%82%A1%E6%83%85%E5%86%B5%E8%A1%A8) As of the reporting period, the company had **22,381** common shareholders, with China Grand Enterprises as the largest shareholder - Total number of common shareholders at the end of the reporting period was **22,381**[15](index=15&type=chunk) | 股东名称 | 股东性质 | 持股比例 | 持股数量 (Shares) | 持有有限售条件的股份数量 (Shares) | 质押、标记或冻结情况 | 数量 (Shares) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | 中国远大集团有限责任公司 | 境内非国有法人 | 41.17% | 209,522,100 | 0 | | | | 连云港金控资本管理有限公司 | 国有法人 | 16.13% | 82,072,000 | 0 | 质押 | 40,000,000 | | 金波 | 境内自然人 | 1.26% | 6,403,681 | 5,158,786 | | | | 宁波至正投资管理有限公司 | 境内非国有法人 | 1.13% | 5,750,253 | 0 | 质押 | 5,750,253 | | 香港中央结算有限公司 | 境外法人 | 0.88% | 4,453,305 | 0 | | | | 朱培元 | 境内自然人 | 0.86% | 4,354,600 | 0 | | | | 上海毓璜投资管理有限公司－毓璜亿保丰壹號私募证券投资基金 | 其他 | 0.84% | 4,261,400 | 0 | | | | 许强 | 境内自然人 | 0.66% | 3,340,457 | 3,255,343 | 质押 | 2,253,200 | | 吴向东 | 境内自然人 | 0.61% | 3,100,000 | 0 | | | | 马敏 | 境内自然人 | 0.47% | 2,400,000 | 0 | | | - The company is unaware of any associated relationships or concerted actions among these shareholders[16](index=16&type=chunk) [Total Number of Preferred Shareholders and Top 10 Preferred Shareholders' Holdings](index=5&type=section&id=%EF%BC%88%E4%BA%8C%EF%BC%89%20%E5%85%AC%E5%8F%B8%E4%BC%98%E5%85%88%E8%82%A1%E8%82%A1%E4%B8%9C%E6%80%BB%E6%95%B0%E5%8F%8A%E5%89%8D%2010%20%E5%90%8D%E4%BC%98%E5%85%88%E8%82%A1%E8%82%A1%E4%B8%9C%E6%8C%81%E8%82%A1%E6%83%85%E5%86%B5%E8%A1%A8) The company has no preferred shareholders - The company has **no preferred shareholders**[17](index=17&type=chunk) [Other Important Matters](index=5&type=section&id=%E4%B8%89%E3%80%81%E5%85%B6%E4%BB%96%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9) This section covers the company's business overview across its main segments and other significant corporate actions [Company Operations](index=5&type=section&id=%EF%BC%88%E4%B8%80%EF%BC%89%E5%85%AC%E5%8F%B8%E7%BB%8F%E8%90%A5) The company operates in trade, oils, and ecological agriculture, aiming to be a high-tech integrated trade-industry enterprise with an ESG focus - Company established in **1994**, listed in **1996**, with main businesses in trade, oils, and ecological agriculture[17](index=17&type=chunk) - Committed to becoming a large-scale high-tech integrated trade-industry enterprise, deeply integrating trade with industry and high technology, adhering to **ESG development principles**[17](index=17&type=chunk) [Trade Segment](index=6&type=section&id=%E8%B4%B8%E6%98%93%E9%A2%86%E5%9F%9F) The company maintains a leading position in bulk commodity trade and is transforming into a platform-based integrated trade service provider - The company primarily engages in energy chemicals, metals, rubber, agricultural products, and other **bulk commodity trade** and foreign trade import/export businesses[18](index=18&type=chunk) - The operating model is shifting towards a new platform-based integrated trade service provider, integrating industrial chain, warehousing logistics, price management, research sharing, and deep industry-trade integration[18](index=18&type=chunk) [Oils Segment](index=6&type=section&id=%E6%B2%B9%E8%84%82%E9%A2%86%E5%9F%9F) The company aims to build a full industrial chain operating model in oils, expanding product lines through the acquisition of FIOP in Malaysia - The company is committed to building a **full industrial chain operating model** integrating resources, R&D, scaled production, and trade[19](index=19&type=chunk) - Successfully acquired **100% equity** of FGV IFFCO Oil Products Sdn Bhd (FIOP), a Malaysian palm oil refinery, in **July 2022** to expand oil product lines and enhance industrial chain synergy[19](index=19&type=chunk) [Ecological Agriculture Segment](index=6&type=section&id=%E7%94%9F%E6%80%81%E5%86%9C%E4%B8%9A%E9%A2%86%E5%9F%9F) The company focuses on plant health, building a high-quality industrial platform through internal development and M&A, with strong emphasis on R&D and collaboration - The company focuses on **plant health**, providing green and environmentally friendly crop management solutions for professional growers[20](index=20&type=chunk) - Its subsidiary, Fujian Kaili Biological Products Co., Ltd., is the **exclusive producer of Zhongshengmycin** raw material and launched the production line for Oryzalin in **October 2022**, entering the plant growth regulator and seed treatment fields[20](index=20&type=chunk) [Other Significant Matters](index=6&type=section&id=%EF%BC%88%E4%BA%8C%EF%BC%89%E5%85%B6%E4%BB%96%E9%87%8D%E5%A4%A7%E4%BA%8B%E9%A1%B9) This section details the uncertain progress of the Shaanxi Microbe acquisition and the completion of the company's share repurchase program [Progress of Shaanxi Microbe Biotechnology Co., Ltd. Equity Acquisition](index=6&type=section&id=1%E3%80%81%E5%85%AC%E5%8F%B8%E5%85%A8%E8%B5%84%E5%AD%90%E5%85%AC%E5%8F%B8%E8%BF%9C%E5%A4%A7%E7%94%9F%E6%80%81%E7%A7%91%E6%8A%80%28%E5%AE%81%E6%B3%A2%29%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8%E4%BA%8E%202021%20%E5%B9%B4%2010%20%E6%9C%88%2029%20%E6%97%A5%E7%AD%BE%E7%BD%B2%E3%80%8A%E9%99%95%E8%A5%BF%E9%BA%A6%E5%8F%AF%E7%BD%97%E7%94%9F%E7%89%A9%E7%A7%91%E6%8A%80%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8%E8%82%A1%E6%9D%83%E8%BD%AC%E8%AE%A9%E6%A1%86%E6%9E%B6%E5%8D%8F%E8%AE%AE%E3%80%8B%EF%BC%8C%E6%8B%9F%E6%94%B6%E8%B4%AD%E9%99%95%E8%A5%BF%E9%BA%A6%E5%8F%AF%E7%BD%97%E7%94%9F%E7%89%A9%E7%A7%91%E6%8A%80%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8%2098.7%25%E8%82%A1%E6%9D%83%E3%80%82%E5%9B%A0%E6%A0%87%E7%9A%84%E5%85%AC%E5%8F%B8%E5%89%8D%E6%9C%9F%E6%9C%AA%E5%8F%8A%E6%97%B6%E3%80%81%E5%85%85%E5%88%86%E5%AE%8C%E6%88%90%E5%AE%A1%E8%AE%A1%E5%87%86%E5%A4%87%E5%B7%A5%E4%BD%9C%E4%BB%A5%E5%8F%8A%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E6%96%B0%E5%86%A0%E8%82%BA%E7%82%8E%E7%96%AB%E6%83%85%E5%A4%9A%E7%82%B9%E7%88%86%E5%8F%91%E7%AD%89%E5%8E%9F%E5%9B%A0%EF%BC%8C%E9%A1%B9%E7%9B%AE%E6%9C%AA%E8%83%BD%E6%8C%89%E6%A1%86%E6%9E%B6%E5%8D%8F%E8%AE%A2%E7%BA%A6%E5%9C%A8%202022%20%E5%B9%B4%203%20%E6%9C%88%2015%20%E6%97%A5%E5%89%8D%E5%87%BA%E5%85%B7%E5%8D%8E%E5%AE%A1%E8%AE%A1%E3%80%81%E8%AF%84%E4%BC%B0%E6%8A%A5%E5%91%8A%E5%B9%B6%E5%BD%B1%E5%93%8D%E4%BA%86%E5%90%8E%E7%BB%AD%E5%B7%A5%E4%BD%9C%E8%BF%9B%E5%B1%95%E3%80%82%E6%88%AA%E8%87%B3%E6%9C%AC%E6%8A%A5%E5%91%8A%E6%97%A5%EF%BC%8C%E8%AF%A5%E9%A1%B9%E7%9B%AE%E5%B7%B2%E5%AE%8C%E6%88%90%E5%AE%A1%E8%AE%A1%E3%80%81%E8%AF%84%E4%BC%B0%E5%B7%A5%E4%BD%9C%EF%BC%8C%E4%BA%A4%E6%98%93%E5%90%84%E6%96%B9%E6%AD%A3%E5%9C%A8%E5%B0%B1%E7%9B%B8%E5%85%B3%E4%BA%8B%E9%A1%B9%E8%BF%9B%E8%A1%8C%E7%A0%94%E5%88%A4%E3%80%81%E6%B4%BD%E8%B0%88%EF%BC%8C%E8%83%BD%E5%90%A6%E6%9C%80%E7%BB%88%E5%AE%9E%E6%96%BD%E6%94%B6%E8%B4%AD%E5%AD%98%E5%9C%A8%E4%B8%8D%E7%A1%AE%E5%AE%9A%E6%80%A7%E3%80%82) The company's proposed acquisition of **98.7%** equity in Shaanxi Microbe Biotechnology faces uncertainty due to audit delays and pandemic impacts - The company's proposed acquisition of **98.7% equity** in Shaanxi Microbe Biotechnology Co., Ltd. faces uncertainty due to audit and valuation delays and the impact of the COVID-19 pandemic[21](index=21&type=chunk)[24](index=24&type=chunk) [Share Repurchase Completion Status](index=6&type=section&id=2%E3%80%81%E5%85%AC%E5%8F%B8%E5%88%86%E5%88%AB%E4%BA%8E%202022%20%E5%B9%B4%204%20%E6%9C%88%206%20%E6%97%A5%E3%80%814%20%E6%9C%88%2022%20%E6%97%A5%E5%8F%AC%E5%BC%80%E7%AC%AC%E5%8D%81%E5%B1%8A%E8%91%A3%E4%BA%8B%E4%BC%9A%202022%20%E5%B9%B4%E5%BA%A6%E7%AC%AC%E4%BA%94%E6%AC%A1%E4%BC%9A%E8%AE%AE%E3%80%812022%20%E5%B9%B4%E5%BA%A6%E7%AC%AC%E4%B8%89%E6%AC%A1%E4%B8%B4%E6%97%B6%E8%82%A1%E4%B8%9C%E5%A4%A7%E4%BC%9A%E5%AE%A1%E8%AE%AE%E9%80%9A%E8%BF%87%E4%BA%86%E3%80%8A%E5%85%B3%E4%BA%8E%E5%85%AC%E5%8F%B8%E5%9B%9E%E8%B4%AD%E8%82%A1%E4%BB%BD%E6%96%B9%E6%A1%88%E7%9A%84%E8%AE%AE%E6%A1%88%E3%80%8B%EF%BC%8C%E6%88%AA%E8%87%B3%202022%20%E5%B9%B4%2010%20%E6%9C%88%2021%20%E6%97%A5%EF%BC%8C%E8%82%A1%E4%BB%BD%E5%9B%9E%E8%B4%AD%E5%B7%B2%E5%AE%8C%E6%88%90%EF%BC%8C%E5%85%AC%E5%8F%B8%E9%80%9A%E8%BF%87%E5%9B%9E%E8%B4%AD%E4%B8%93%E7%94%A8%E8%AF%81%E5%88%B8%E8%B4%A6%E6%88%B7%EF%BC%8C%E4%BB%A5%E9%9B%86%E4%B8%AD%E7%AB%9E%E4%BB%B7%E6%96%B9%E5%BC%8F%E5%9B%9E%E8%B4%AD%E5%85%AC%E5%8F%B8%E8%82%A1%E4%BB%BD%202%2C313%2C600%20%E8%82%A1%EF%BC%8C%E5%8D%A0%E5%85%AC%E5%8F%B8%E6%80%BB%E8%82%A1%E6%9C%AC%E7%9A%84%200.45%25%EF%BC%8C%E6%9C%80%E9%AB%98%E6%88%90%E4%BA%A4%E4%BB%B7%E4%B8%BA%2013.57%20%E5%85%83%2F%E8%82%A1%EF%BC%8C%E6%9C%80%E4%BD%8E%E6%88%90%E4%BA%A4%E4%BB%B7%E4%B8%BA%209.36%20%E5%85%83%2F%E8%82%A1%EF%BC%8C%E6%94%AF%E4%BB%98%E7%9A%84%E6%80%BB%E9%87%91%E9%A2%9D%E4%B8%BA%2030%2C000%2C778%20%E5%85%83%EF%BC%88%E4%B8%8D%E5%90%AB%E4%BA%A4%E6%98%93%E8%B4%B9%E7%94%A8%EF%BC%89%E3%80%82%E5%9B%9E%E8%B4%AD%E8%82%A1%E4%BB%BD%E5%B7%A5%E4%BD%9C%E7%9A%84%E5%AE%9E%E6%96%BD%E7%AC%A6%E5%90%88%E7%9B%B8%E5%85%B3%E6%B3%95%E5%BE%8B%E6%B3%95%E8%A7%84%E7%9A%84%E8%A6%81%E6%B1%82%EF%BC%8C%E7%AC%A6%E5%90%88%E5%85%AC%E5%8F%B8%E6%97%A2%E5%AE%9A%E7%9A%84%E5%9B%9E%E8%B4%AD%E6%96%B9%E6%A1%88%E3%80%82) The company completed its share repurchase program on **October 21, 2022**, repurchasing **2,313,600 shares**, representing **0.45%** of total share capital - The company completed its share repurchase on **October 21, 2022**, repurchasing **2,313,600 shares**, accounting for **0.45%** of the total share capital[22](index=22&type=chunk)[24](index=24&type=chunk) - The highest transaction price for repurchased shares was **CNY 13.57/share**, the lowest was **CNY 9.36/share**, with a total payment of **CNY 30,000,778**[22](index=22&type=chunk) [Quarterly Financial Statements](index=7&type=section&id=%E5%9B%9B%E3%80%81%E5%AD%A3%E5%BA%A6%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) This section presents the company's consolidated balance sheet, income statement, and cash flow statement for the quarter [Consolidated Balance Sheet](index=7&type=section&id=1%E3%80%81%E5%90%88%E5%B9%B6%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) As of **September 30, 2022**, total assets were **CNY 8,986,884,260.53**, a **17.80%** increase from the beginning of the year | 项目 | 2022年9月30日 (CNY) | 2022年1月1日 (CNY) | | :--- | :--- | :--- | | **资产** | | | | 流动资产合计 | 7,682,096,362.55 | 6,605,743,041.89 | | 非流动资产合计 | 1,304,787,897.98 | 1,023,137,269.14 | | **资产总计** | **8,986,884,260.53** | **7,628,880,311.03** | | **负债** | | | | 流动负债合计 | 5,171,871,380.29 | 4,083,794,761.74 | | 非流动负债合计 | 513,954,256.25 | 445,617,103.02 | | **负债合计** | **5,685,825,636.54** | **4,529,411,864.76** | | **所有者权益** | | | | 归属于母公司所有者权益合计 | 3,024,294,598.51 | 2,880,831,939.26 | | 少数股东权益 | 276,764,025.48 | 218,636,507.01 | | **所有者权益合计** | **3,301,058,623.99** | **3,099,468,446.27** | | **负债和所有者权益总计** | **8,986,884,260.53** | **7,628,880,311.03** | [Consolidated Income Statement from Year-Beginning to End of Reporting Period](index=9&type=section&id=2%E3%80%81%E5%90%88%E5%B9%B6%E5%B9%B4%E5%88%9D%E5%88%B0%E6%8A%A5%E5%91%8A%E6%9C%9F%E6%9C%AB%E5%88%A9%E6%B6%A6%E8%A1%A8) Year-to-date total operating revenue was **CNY 61,661,629,248.21**, with net profit attributable to parent company shareholders at **CNY 121,093,980.48** | 项目 | 本期发生额 (CNY) | 上期发生额 (CNY) | | :--- | :--- | :--- | | 营业总收入 | 61,661,629,248.21 | 60,078,565,970.03 | | 营业总成本 | 61,711,829,660.51 | 59,836,007,759.83 | | 营业利润 | 219,337,850.53 | 314,837,519.20 | | 利润总额 | 231,255,335.54 | 323,557,920.26 | | 净利润 | 159,580,091.57 | 261,956,084.21 | | 归属于母公司股东的净利润 | 121,093,980.48 | 213,511,259.22 | | 少数股东损益 | 38,486,111.09 | 48,444,824.99 | | 综合收益总额 | 218,685,312.61 | 258,286,027.37 | | 基本每股收益 | 0.24 | 0.41 | | 稀释每股收益 | 0.24 | 0.41 | [Consolidated Cash Flow Statement from Year-Beginning to End of Reporting Period](index=11&type=section&id=3%E3%80%81%E5%90%88%E5%B9%B6%E5%B9%B4%E5%88%9D%E5%88%B0%E6%8A%A5%E5%91%8A%E6%9C%9F%E6%9C%AB%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) From year-beginning to the end of the reporting period, operating, investing, and financing cash flows all saw significant year-on-year decreases | 项目 | 本期发生额 (CNY) | 上期发生额 (CNY) | | :--- | :--- | :--- | | 经营活动产生的现金流量净额 | 57,908,724.46 | 307,949,261.94 | | 投资活动产生的现金流量净额 | 70,131,150.06 | 638,327,406.91 | | 筹资活动产生的现金流量净额 | 153,649,007.26 | 360,188,841.29 | | 汇率变动对现金及现金等价物的影响 | 123,935,041.02 | -1,393,107.25 | | 现金及现金等价物净增加额 | 405,623,922.80 | 1,305,072,402.89 | | 期末现金及现金等价物余额 | 2,844,191,248.56 | 2,409,527,305.21 | [Audit Report](index=12&type=section&id=%EF%BC%88%E4%BA%8C%EF%BC%89%20%E5%AE%A1%E8%AE%A1%E6%8A%A5%E5%91%8A) This section confirms that the company's **2022** third-quarter report is unaudited [Audit Report](index=12&type=section&id=%E5%AE%A1%E8%AE%A1%E6%8A%A5%E5%91%8A) The company's **2022** third-quarter report is unaudited - The company's third-quarter report is **unaudited**[35](index=35&type=chunk)